810
Views
5
CrossRef citations to date
0
Altmetric
Review Article

Maintenance rituximab in follicular non-Hodgkin lymphoma: facts and controversies

, &
Pages 770-778 | Received 04 Jul 2011, Accepted 24 Sep 2011, Published online: 24 Oct 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Chadi Nabhan, Nicholas J. Ollberding, Dana Villines, Brian C.-H. Chiu, Donne Bennett D. Caces, Tina V. Valdez, Michele Ghielmini, Shu-Fang Hsu Schmitz & Sonali M. Smith. (2014) A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. Leukemia & Lymphoma 55:6, pages 1288-1294.
Read now

Articles from other publishers (3)

Mark Roschewski & Brian T. Hill. (2019) One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?. American Society of Clinical Oncology Educational Book:39, pages 467-476.
Crossref
Janette Greenhalgh, Adrian Bagust, Angela Boland, Michaela Blundell, James Oyee, Sophie Beale, Yenal Dundar, Juliet Hockenhull, Chris Proudlove & Patrick Chu. (2013) Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma. PharmacoEconomics 31:5, pages 403-413.
Crossref
Bijal D. Shah, Peter MartinEduardo M. Sotomayor. (2012) Mantle Cell Lymphoma: A Clinically Heterogeneous Disease in Need of Tailored Approaches. Cancer Control 19:3, pages 227-235.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.